A Single Mutation of the Fumarylacetoacetate Hydrolase Gene in French Canadians with Hereditary Tyrosinemia Type I
- 11 August 1994
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (6), 353-357
- https://doi.org/10.1056/nejm199408113310603
Abstract
Hereditary tyrosinemia type I is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. The disorder clusters in the Saguenay-Lac-St.-Jean area of Quebec. In this region, 1 of 1846 newborns is affected and 1 of every 22 persons is thought to be a carrier. Recently, we identified a splice mutation and two nonsense mutations in the fumarylacetoacetate hydrolase gene in two patients from Quebec with tyrosinemia type I. We used allele-specific-oligonucleotide hybridization to examine the frequency of these three candidate mutations in patients with tyrosinemia type I and in the population of Quebec. The splice mutation was found in 100 percent of patients from the Saguenay-Lac-St.-Jean area and in 28 percent of patients from other regions of the world. Of 25 patients from the Saguenay-Lac-St.-Jean region, 20 (80 percent) were homozygous for this mutation, a guanine-to-adenine change in the splice-donor sequence in intron 12 of the gene, indicating that it causes most cases of tyrosinemia type I in the region. The frequency of carrier status, based on screening of blood spots from newborns, was about 1 per 25 in the Saguenay-Lac-St.-Jean population and about 1 per 66 overall in Quebec. This study identified the most prevalent mutation causing hereditary tyrosinemia in French Canada; it also showed the feasibility of DNA-based testing for carriers in the population at risk.Keywords
This publication has 16 references indexed in Scilit:
- Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenaseThe Lancet, 1992
- Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.Journal of Clinical Investigation, 1992
- Liver transplantation in tyrosinaemia type 1: the dilemma of timing the operationActa Paediatrica, 1992
- Cystic fibrosis mutations in French Canadians: Three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosisAmerican Journal of Medical Genetics, 1992
- Five mutations at the PAH locus account for almost 90% of PKU mutations in French-Canadians from eastern QuebecHuman Mutation, 1992
- Neurologic Crises in Hereditary TyrosinemiaNew England Journal of Medicine, 1990
- Nucleotide sequence of cDNA encoding human fumarylacetoacetaseNucleic Acids Research, 1990
- Deletion in the Gene for the Low-Density-Lipoprotein Receptor in a Majority of French Canadians with Familial HypercholesterolemiaNew England Journal of Medicine, 1987
- Deficient Fumarylacetoacetate Fumarylhydrolase Activity in Lymphocytes and Fibroblasts from Patients with Hereditary TyrosinemiaPediatric Research, 1983
- On the enzymic defects in hereditary tyrosinemia.Proceedings of the National Academy of Sciences, 1977